{"entity":{"id":"psmd13","kind":"target","name":"PSMD13","aka":["proteasome 26S subunit, non-ATPase 13","26S proteasome non-ATPase regulatory subunit 13","p40.5","Rpn9"],"tldr":"PSMD13 (26S proteasome non-ATPase regulatory subunit 13) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","summary":"Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair.\n\nOpen Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.64, genetic association 0.03, clinical 0.99).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:9558","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9558"},{"label":"UniProt Q9UNM6","url":"https://www.uniprot.org/uniprotkb/Q9UNM6/entry"},{"label":"NCBI Gene 5719","url":"https://www.ncbi.nlm.nih.gov/gene/5719"},{"label":"Ensembl ENSG00000185627","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185627"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":["multiple-myeloma","non-hodgkin-lymphoma","mantle-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.99. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"PSMD13","role":["drug-target"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:9558","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9558","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q9UNM6","url":"https://www.uniprot.org/uniprotkb/Q9UNM6/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000185627","url":"https://platform.opentargets.org/target/ENSG00000185627/associations","note":"association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: plasma cell myeloma 0.60, non-Hodgkin lymphoma 0.57, mantle cell lymphoma 0.54 (GraphQL API, CC0)"}],"specificity":"broadly-expressed","distribution":"few-types","specificityNote":"Broadly expressed or essential: HPA lists PSMD13 among essential proteins and finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA PSMD13: RNA low tissue specificity; high antibody staining in 5 normal tissues; highest cancer staining testis cancer (7 of 11 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Multiple myeloma, Lymphoma); Open Targets associates it with 2 specific cancer types at or above 0.5 (plasma cell myeloma, mantle cell lymphoma). (Rule 7 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas PSMD13 tissue","url":"https://www.proteinatlas.org/ENSG00000185627-PSMD13/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000185627 associations","url":"https://platform.opentargets.org/target/ENSG00000185627/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:9558","ensembl":"ENSG00000185627","uniprot":"Q9UNM6","entrez":"5719","firstDescribed":1998,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Hori et al, Gene, 1998, \"cDNA cloning and functional analysis of p28 (Nas6p) and p40.5 (Nas7p), two novel regulatory subunits of the 26S proteasome\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/9714768/","biology":"Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair. Locus 11p15.5 (HGNC).","whereFound":["Multiple myeloma: Open Targets association 0.60 with plasma cell myeloma (MONDO_0009693)","Non-Hodgkin lymphoma: Open Targets association 0.57 with non-Hodgkin lymphoma (MONDO_0018908)","Mantle cell lymphoma: Open Targets association 0.54 with mantle cell lymphoma (MONDO_0018876)"],"targetClass":"other","prevalence":[]},"route":"/targets/psmd13/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}]}}